{"id":48334,"date":"2022-09-13T23:02:12","date_gmt":"2022-09-13T21:02:12","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/aditxt-inc-nasdaq-adtx-announces-1-for-50-reverse-stock-split-effective-pre-market-opening-on-september-14-2022\/"},"modified":"2022-09-13T23:02:12","modified_gmt":"2022-09-13T21:02:12","slug":"aditxt-inc-nasdaq-adtx-announces-1-for-50-reverse-stock-split-effective-pre-market-opening-on-september-14-2022","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/aditxt-inc-nasdaq-adtx-announces-1-for-50-reverse-stock-split-effective-pre-market-opening-on-september-14-2022\/","title":{"rendered":"Aditxt, Inc. (Nasdaq: ADTX) Announces 1-for-50 Reverse Stock Split Effective Pre-Market Opening on September 14, 2022"},"content":{"rendered":"
\n

RICHMOND, Va.–(BUSINESS WIRE)–Aditxt, Inc. (Nasdaq: ADTX), a biotech innovation company developing and commercializing technologies focused on monitoring and modulating the immune system, announced today that it will effect a 1-for-50 reverse split of its common stock effective as of 4:01 p.m. Eastern Time on September 13, 2022. Commencing with the opening of trading on The Nasdaq Capital Market on September 14, 2022, the Company\u2019s common stock will trade on a post-split basis under the same symbol ADTX. The reverse stock split was approved by the Company\u2019s stockholders at the special meeting held on September 7, 2022, with the final ratio determined by the Company\u2019s board of directors.\n<\/p>\n

\nAs a result of the reverse stock split, the CUSIP number for the Company\u2019s common stock will now be 007025505. As a result of the reverse stock split, every 50 shares of issued and outstanding common stock will be exchanged for 1 share of common stock, with any fractional shares being rounded up to the next higher whole share. Immediately after the reverse stock split becomes effective, the Company will have approximately 1,156,674 shares of common stock issued and outstanding.\n<\/p>\n

\nThe reverse stock split is primarily intended to bring the Company into compliance with Nasdaq\u2019s $1.00 per share minimum bid price requirement for continued listing.\n<\/p>\n

\nAdditional information concerning the reverse stock split can be found in Aditxt\u2019s definitive proxy statement filed with the Securities and Exchange Commission on August 1, 2022, as amended.\n<\/p>\n

\nAbout Aditxt, Inc.<\/strong>\n<\/p>\n

\nAditxt is a biotech innovation company developing and commercializing technologies focused on monitoring and modulating the immune system. Aditxt\u2019s immune monitoring technologies are designed to provide a personalized immune profile. Aditxt\u2019s immune modulating technologies, currently preclinical, are being developed to retrain the immune system to induce tolerance to address rejection of transplanted organs, autoimmune diseases and allergies. For more information, please visit www.Aditxt.com <\/a>and www.AditxtScore.com<\/a>\n<\/p>\n

\nForward-Looking Statements<\/strong>\n<\/p>\n

\nThis release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. All forward-looking statements are inherently uncertain as they are based on current expectations and assumptions concerning future events or future performance of the company. Readers are cautioned not to place undue reliance on these forward-looking statements, which are only predictions and speak only as of the date hereof. In evaluating such statements, prospective investors should review carefully various risks and uncertainties identified in this release and matters set in the company’s SEC filings. These risks and uncertainties could cause the company’s actual results to differ materially from those indicated in the forward-looking statements.\n<\/p>\n

Contacts<\/b> <\/p>\n

\nMedia and Investor Relations Contact:
\n
ir@aditxt.com<\/a>
www.aditxt.com<\/a>\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

RICHMOND, Va.–(BUSINESS WIRE)–Aditxt, Inc. (Nasdaq: ADTX), a biotech innovation company developing and commercializing technologies focused on monitoring and modulating the immune system, announced today that it will effect a 1-for-50 reverse split of its common stock effective as of 4:01 p.m. Eastern Time on September 13, 2022. Commencing with the opening of trading on The … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-48334","6":"format-standard","7":"category-industry"},"yoast_head":"\nAditxt, Inc. (Nasdaq: ADTX) Announces 1-for-50 Reverse Stock Split Effective Pre-Market Opening on September 14, 2022 - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/aditxt-inc-nasdaq-adtx-announces-1-for-50-reverse-stock-split-effective-pre-market-opening-on-september-14-2022\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Aditxt, Inc. (Nasdaq: ADTX) Announces 1-for-50 Reverse Stock Split Effective Pre-Market Opening on September 14, 2022 - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"RICHMOND, Va.–(BUSINESS WIRE)–Aditxt, Inc. (Nasdaq: ADTX), a biotech innovation company developing and commercializing technologies focused on monitoring and modulating the immune system, announced today that it will effect a 1-for-50 reverse split of its common stock effective as of 4:01 p.m. Eastern Time on September 13, 2022. Commencing with the opening of trading on The ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/aditxt-inc-nasdaq-adtx-announces-1-for-50-reverse-stock-split-effective-pre-market-opening-on-september-14-2022\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2022-09-13T21:02:12+00:00\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/aditxt-inc-nasdaq-adtx-announces-1-for-50-reverse-stock-split-effective-pre-market-opening-on-september-14-2022\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/aditxt-inc-nasdaq-adtx-announces-1-for-50-reverse-stock-split-effective-pre-market-opening-on-september-14-2022\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Aditxt, Inc. (Nasdaq: ADTX) Announces 1-for-50 Reverse Stock Split Effective Pre-Market Opening on September 14, 2022\",\"datePublished\":\"2022-09-13T21:02:12+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/aditxt-inc-nasdaq-adtx-announces-1-for-50-reverse-stock-split-effective-pre-market-opening-on-september-14-2022\\\/\"},\"wordCount\":462,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/aditxt-inc-nasdaq-adtx-announces-1-for-50-reverse-stock-split-effective-pre-market-opening-on-september-14-2022\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/aditxt-inc-nasdaq-adtx-announces-1-for-50-reverse-stock-split-effective-pre-market-opening-on-september-14-2022\\\/\",\"name\":\"Aditxt, Inc. (Nasdaq: ADTX) Announces 1-for-50 Reverse Stock Split Effective Pre-Market Opening on September 14, 2022 - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"datePublished\":\"2022-09-13T21:02:12+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/aditxt-inc-nasdaq-adtx-announces-1-for-50-reverse-stock-split-effective-pre-market-opening-on-september-14-2022\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/aditxt-inc-nasdaq-adtx-announces-1-for-50-reverse-stock-split-effective-pre-market-opening-on-september-14-2022\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/aditxt-inc-nasdaq-adtx-announces-1-for-50-reverse-stock-split-effective-pre-market-opening-on-september-14-2022\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Aditxt, Inc. (Nasdaq: ADTX) Announces 1-for-50 Reverse Stock Split Effective Pre-Market Opening on September 14, 2022\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Aditxt, Inc. (Nasdaq: ADTX) Announces 1-for-50 Reverse Stock Split Effective Pre-Market Opening on September 14, 2022 - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/aditxt-inc-nasdaq-adtx-announces-1-for-50-reverse-stock-split-effective-pre-market-opening-on-september-14-2022\/","og_locale":"en_US","og_type":"article","og_title":"Aditxt, Inc. (Nasdaq: ADTX) Announces 1-for-50 Reverse Stock Split Effective Pre-Market Opening on September 14, 2022 - Pharma Trend","og_description":"RICHMOND, Va.–(BUSINESS WIRE)–Aditxt, Inc. (Nasdaq: ADTX), a biotech innovation company developing and commercializing technologies focused on monitoring and modulating the immune system, announced today that it will effect a 1-for-50 reverse split of its common stock effective as of 4:01 p.m. Eastern Time on September 13, 2022. Commencing with the opening of trading on The ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/aditxt-inc-nasdaq-adtx-announces-1-for-50-reverse-stock-split-effective-pre-market-opening-on-september-14-2022\/","og_site_name":"Pharma Trend","article_published_time":"2022-09-13T21:02:12+00:00","author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/aditxt-inc-nasdaq-adtx-announces-1-for-50-reverse-stock-split-effective-pre-market-opening-on-september-14-2022\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/aditxt-inc-nasdaq-adtx-announces-1-for-50-reverse-stock-split-effective-pre-market-opening-on-september-14-2022\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Aditxt, Inc. (Nasdaq: ADTX) Announces 1-for-50 Reverse Stock Split Effective Pre-Market Opening on September 14, 2022","datePublished":"2022-09-13T21:02:12+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/aditxt-inc-nasdaq-adtx-announces-1-for-50-reverse-stock-split-effective-pre-market-opening-on-september-14-2022\/"},"wordCount":462,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/aditxt-inc-nasdaq-adtx-announces-1-for-50-reverse-stock-split-effective-pre-market-opening-on-september-14-2022\/","url":"https:\/\/pharma-trend.com\/en\/aditxt-inc-nasdaq-adtx-announces-1-for-50-reverse-stock-split-effective-pre-market-opening-on-september-14-2022\/","name":"Aditxt, Inc. (Nasdaq: ADTX) Announces 1-for-50 Reverse Stock Split Effective Pre-Market Opening on September 14, 2022 - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"datePublished":"2022-09-13T21:02:12+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/aditxt-inc-nasdaq-adtx-announces-1-for-50-reverse-stock-split-effective-pre-market-opening-on-september-14-2022\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/aditxt-inc-nasdaq-adtx-announces-1-for-50-reverse-stock-split-effective-pre-market-opening-on-september-14-2022\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/aditxt-inc-nasdaq-adtx-announces-1-for-50-reverse-stock-split-effective-pre-market-opening-on-september-14-2022\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Aditxt, Inc. (Nasdaq: ADTX) Announces 1-for-50 Reverse Stock Split Effective Pre-Market Opening on September 14, 2022"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/48334","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=48334"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/48334\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=48334"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=48334"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=48334"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}